Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice

Vaccine

Volumn 26, Issue 47, 2008, Pages 5928-5934

  Kim, Tae S ^a   Lee, Byeong C ^a   Kim, Eugene ^a   Cho, Daeho ^b   Cohen, Edward P ^c  

^a Korea University   (South Korea)

^b Sookmyung Women's University   (South Korea)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

AIMP1; B7.1; Fibroblast; Tumor immunity; Vaccine

Indexed keywords

CD8 ANTIGEN; EPITOPE; GENE PRODUCT; INTERLEUKIN 12; OVALBUMIN; PROTEIN AIMP1; PROTEIN B7.1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; FEMALE; FIBROBLAST; GENE TRANSFER; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; CYTOKINES; EPITOPES; FEMALE; FIBROBLASTS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASMS; OVALBUMIN; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 55049085234     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.051     Document Type: Article

References (41)

1. Tirapu I., Huarte E., Guiducci C., Arina A., Zaratiegui M., Murillo O., et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res 66 (2006) 2442-2450
2. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267-296
3. Kim R., Emi M., and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121 (2007) 1-14
4. Ribas A., Butterfield L.H., Glaspy J.A., and Economou J.S. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther 2 (2002) 57-78
5. + CTL response. J Cancer Res Clin Oncol 131 (2005) 468-478
6. Copier J., and Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 25 (2006) 297-319
7. Wysocki P.J., Karczewska-Dzionk A., Mackiewicz-Wysocka M., and Mackiewicz A. Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 4 (2004) 1595-1607
8. Tahara H., Zeh H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54 (1994) 182-189
9. Kim T.S., Jung M.Y., Cho D., and Cohen E.P. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells. Vaccine 24 (2006) 6564-6573
10. Peron J.M., Bureau C., Gourdy P., Lulka H., Souque A., Calippe B., et al. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity. Gut 56 (2007) 107-114
11. Sigal L.J., Reiser H., and Rock K.L. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J Immunol 161 (1998) 2740-2745
12. Daniel P.T., Kroidl A., Cayeux S., Bargou R., Blankenstein T., and Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 159 (1997) 3808-3815
13. Yang S., Hodge J.W., Grosenbach D.W., and Schlom J. Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 175 (2005) 3715-3723
14. Lee S.W., Cho B.H., Park S.G., and Kim S. Aminoacyl-tRNA synthetase complexes: beyond translation. J Cell Sci 117 (2004) 3725-3734
15. Park S.G., Ewalt K.L., and Kim S. Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci 30 (2005) 569-574
16. Park S.G., Kang Y.S., Kim J.Y., Lee C.S., Ko Y.G., Lee W.J., et al. Hormonal activity of AIMP1/p43 for glucose homeostasis. Proc Natl Acad Sci USA 103 (2006) 14913-14918
17. + T cells. J Immunol 176 (2006) 256-264
18. Kim E., Kim S.H., Kim S., Cho D., and Kim T.S. AIMP1/p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability. J Immunol 180 (2008) 2894-2902
19. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54 (2005) 721-728
20. Chattopadhyay S., and Chakraborty N.G. Continuous presence of Th1 conditions is necessary for longer lasting tumor-specific CTL activity in stimulation cultures with PBL. Hum Immunol 66 (2005) 884-891
21. Zhang Y., Wakita D., Chamoto K., Narita Y., Matsubara N., Kitamura H., et al. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol 19 (2007) 151-161
22. Kawashima I., Tai V., Southwood S., Takesako K., Sette A., and Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59 (1999) 431-435
23. Kim T.S., Chung S.W., Kim S.H., Kang B.Y., Hwang S.Y., and Lee J.W. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of antigen-specific CTL and protection against tumor development in vivo. Cancer Gene Ther 7 (2000) 861-870
24. Kim T.S., and Cohen E.P. Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells. J Immunother 16 (1994) 24-35
25. Koski I.R., Poplack D.G., and Blaese R.M. A nonspecific stain for the determination of moncytes and macrophages. In: Bloom B.R., and David J.R. (Eds). In vitro methods in cell-mediated and tumor immunity (1976), Academic Press, New York, NY 359-362
26. Podhajcer O.L., Lopez M.V., and Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 18 (2007) 183-194
27. Wakimoto H., Abe J., Tsunoda R., Aoyagi M., Hirakawa K., and Hamada H. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56 (1996) 1828-1833
28. Addison C.L., Bramson J.L., Hitt M.M., Muller W.J., Gauldie J., and Graham F.L. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5 (1998) 1400-1409
29. Lopez M.V., Adris S.K., Bravo A.I., Chernajovsky Y., and Podhajcer O.L. IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis. J Immunol 175 (2005) 5885-5894
30. Rosenthal F.M., Cronin K., Bannerji R., Golde D.W., and Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Blood 83 (1994) 1289-1298
31. Oniki S., Nagai H., Horikawa J., Furukawa J., Belladonna M.L., Yoshimoto T., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 66 (2006) 6395-6404
32. Ge N.L., Ye S.L., Zheng N., Sun R.X., Liu Y.K., and Tang Z.Y. Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines. World J Gastroenterol 9 (2003) 2182-2185
33. Kim T.S., Chung S.W., and Hwang S.Y. Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7. Vaccine 18 (2000) 2886-2894
34. O-Sullivan I., Chopra A., Kim T.S., Magnuson S., Falduto M.T., Huang J., et al. New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice. Cancer Gene Ther 14 (2007) 389-398
35. Zheng S.Y., Li D.C., Zhang Z.D., Zhao J., and Ge J.F. Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells. World J Gastroenterol 11 (2005) 3204-3211
36. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996) 233-258
37. Ward R.C., and Kaufman H.L. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol 26 (2007) 161-196
38. Traversari C., Meazza R., Coppolecchia M., Basso S., Verrecchia A., Van Der Bruggen P., et al. IFN-gamma gene transfer restores HLA-class I expression and MAGE-3 antigen presentation to CTL in HLA-deficient small cell lung cancer. Gene Ther 4 (1997) 1029-1035
39. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13 (1995) 399-415
40. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199 (2004) 9-26
41. Wilson N.S., and Villadangos J.A. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 86 (2005) 241-305